Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Reducing Bleeding Risk in Fibroid Surgery Using Misoprostol for Patients Undergoing Myomectomy

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a medication called Misoprostol in patients undergoing surgery for fibroids, which are non-cancerous growths in the uterus. The study aims to see if Misoprostol can help reduce blood loss during these surgeries. Participants in the study will be divided into two groups: one group will receive Misoprostol, and the other group will receive a placebo, which looks like the medication but does not contain any active ingredients.

The purpose of the study is to evaluate how Misoprostol affects blood loss during the surgical removal of fibroids, known as a myomectomy. Participants will take the medication or placebo before their surgery, and researchers will measure the amount of blood lost during the procedure. The study will also look at other factors, such as changes in hemoglobin levels, which is a protein in red blood cells that carries oxygen, and the length of hospital stay after surgery.

Throughout the study, researchers will compare the results between the group taking Misoprostol and the group taking the placebo. This will help determine if Misoprostol is effective in reducing blood loss and improving outcomes for patients undergoing myomectomy for fibroids. The study is expected to continue until December 2026, with recruitment starting in October 2024.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed based on criteria such as age (18 to 43 years), presence of symptomatic myomas (fibroids), and the need for a myomectomy (surgical removal of fibroids).

  2. Step 2

    Randomization

    Participants are randomly assigned to one of two groups: the experimental group receiving misoprostol or the control group receiving a placebo.

  3. Step 3

    Medication administration

    Participants in the experimental group receive a single dose of misoprostol 400 micrograms orally. Participants in the control group receive a placebo tablet.

  4. Step 4

    Surgical procedure

    The surgical procedure, myomectomy, is performed. The type of surgery (laparoscopy or laparotomy) depends on the size and number of fibroids.

  5. Step 5

    Intraoperative assessment

    During surgery, blood loss is measured in milliliters by assessing the volume in suction devices and blood-soaked compresses.

  6. Step 6

    Postoperative evaluation

    Postoperative evaluations include comparing hemoglobin levels before and after surgery, and at one month post-surgery. Other factors such as demographic characteristics, fibroid characteristics, and early postoperative complications are also assessed.

  7. Step 7

    Follow-up

    Follow-up assessments occur at specified intervals to monitor recovery and any complications. The length of hospitalization and recovery progress are documented.

Who can join the trial?

5 criteria

  • Patient must be a woman aged between 18 and 43 years old.
  • Patient must have **symptomatic myomas**, which means fibroids causing symptoms like bleeding, pain, or difficulty getting pregnant.
  • If the patient needs a **myomectomy** (surgery to remove fibroids) by **laparoscopy** (a type of surgery done through small cuts), the fibroid should be 10 cm or smaller, or there should be 4 or fewer fibroids.
  • If the patient needs a myomectomy by **laparotomy** (a type of surgery done through a larger cut), the fibroid should be larger than 10 cm, or there should be more than 4 fibroids.
  • It must be possible to perform **OTAU** during the surgery, which involves placing a clip on the uterine artery and using a special device called a turnstile.

Who cannot join the trial?

8 criteria

  • Participants must not have any other medical conditions that could interfere with the study.
  • Participants must not be pregnant or breastfeeding.
  • Participants must not have a history of allergic reactions to the study medication.
  • Participants must not be taking any medications that could interfere with the study results.
  • Participants must not have any significant health issues that could pose a risk during the study.
  • Participants must not have participated in another clinical trial recently.
  • Participants must not have a history of substance abuse.
  • Participants must not have any mental health conditions that could affect their ability to participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Misoprostol is a medication used in this clinical trial to help reduce the risk of bleeding during a surgical procedure called myomectomy. Myomectomy is a surgery to remove fibroids from the uterus. In this study, misoprostol is given to patients to see if it can help decrease the amount of blood lost during the surgery.

What is already known about the treatment

Misoprostol – Misoprostol is administered orally in the form of tablets. It is currently being studied in clinical trials for its potential to reduce blood loss during surgical procedures, specifically myomectomies. The main therapeutic indication for Misoprostol in this context is to prevent excessive bleeding during surgery. At the molecular level, Misoprostol works by binding to prostaglandin receptors, leading to increased uterine contractions and reduced bleeding. It is classified pharmacologically as a prostaglandin analog.

Investigated diseases

Fibroma – Fibroma is a benign tumor composed mainly of fibrous or connective tissue. It typically develops in the uterus, skin, or other organs. These growths are usually non-cancerous and can vary in size. They may cause symptoms depending on their location and size, such as discomfort or pressure on nearby organs. Fibromas grow slowly and may remain stable for long periods. In some cases, they may not require any intervention unless they cause significant symptoms.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-513617-13-00Protocol codeRBHP 2024 GREMEAUEstimated enrolment80 patientsSponsorUniversity Hospital Of Clermont-Ferrand

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).